TAK-659 in combination with NKTR-214 and anti-PD-1 therapy leads to complete and sustained tumor regression and immune memory in pre-clinical syngeneic models.-MedSci.cn

TAK-659 in combination with NKTR-214 and anti-PD-1 therapy leads to complete and sustained tumor regression and immune memory in pre-clinical syngeneic models.

Yu, J; Sappal, JH; Zhang, MK; Kannan, K; Zalevsky, J

JOURNAL OF CLINICAL ONCOLOGY, 2018; 36 (15):

科室
- - 订阅+
  - 更多科室
工具
服务